These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 35937253)

  • 1. Nimotuzumab Increases the Recovery Rate of Severe and Critical COVID-19 Patients: Evaluation in the Real-World Scenario.
    Diaz H; Jiménez J; Hernández A; Valdés L; Martínez A; Porto L; Hernández R; Travieso N; Jova JH; Medel L; Troche M; Gorte A; Batista D; Valls AR; Cabrera L; Domeq M; Pérez L; Lorenzo-Luaces P; Sánchez L; Saavedra D; Ramos M; Crombet T
    Front Public Health; 2022; 10():948520. PubMed ID: 35937253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blocking EGFR with nimotuzumab: a novel strategy for COVID-19 treatment.
    Londres HD; Armada JJ; Martínez AH; Abdo Cuza AA; Sánchez YH; Rodríguez AG; Figueroa SS; Llanez Gregorich EM; Torres Lahera ML; Peire FG; González TM; González YZ; Añé Kouri AL; Palomo AG; Concepción MT; Pérez LM; Luaces-Alvarez PL; Iglesias DE; Hernández DS; Suzarte MR; Ramos TC
    Immunotherapy; 2022 May; 14(7):521-530. PubMed ID: 35306855
    [No Abstract]   [Full Text] [Related]  

  • 3. Nimotuzumab for COVID-19: case series.
    Abdo Cuza AA; Ávila JP; Martínez RM; González JJ; Aspuro GP; Gutiérrez Martínez JA; Suzarte MR; Hernández DS; Añé-Kouri AL; Ramos TC
    Immunotherapy; 2021 Nov; ():. PubMed ID: 34806405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune, inflammatory and prothrombotic parameters in COVID-19 patients treated with an anti EGFR antibody.
    Saavedra D; Añé-Kourí AL; Gregorich EML; Mena J; Lorenzo-Luaces P; Londres HD; Martínez AH; Armada JJ; Sánchez YH; González YZ; Troche M; Medel L; Ramos M; Crombet T
    Immunol Lett; 2022 Dec; 251-252():1-8. PubMed ID: 36174772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regdanvimab in patients with mild-to-moderate SARS-CoV-2 infection: A propensity score-matched retrospective cohort study.
    Lee S; Lee SO; Lee JE; Kim KH; Lee SH; Hwang S; Kim SW; Chang HH; Kim Y; Bae S; Kim AS; Kwon KT
    Int Immunopharmacol; 2022 May; 106():108570. PubMed ID: 35168079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ivermectin for preventing and treating COVID-19.
    Popp M; Stegemann M; Metzendorf MI; Gould S; Kranke P; Meybohm P; Skoetz N; Weibel S
    Cochrane Database Syst Rev; 2021 Jul; 7(7):CD015017. PubMed ID: 34318930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world evaluation of the impact of two anti-SARS-CoV-2 monoclonal antibody regimens on COVID-19 hospitalizations in older adults.
    Sobolewski KA; Smoke SM; Brophy A; Vassallo AV; Chen B; Hilden P; Patterson R; Pittiglio M; Raja K; Handler E; Freer C
    J Med Virol; 2022 Jun; 94(6):2493-2499. PubMed ID: 35199356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
    Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
    Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
    Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
    Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overall Survival of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Treated with Nimotuzumab in the Real World.
    Saumell Y; Sanchez L; González S; Ortiz R; Medina E; Galán Y; Lage A
    Adv Ther; 2017 Dec; 34(12):2638-2647. PubMed ID: 29134427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial.
    Solomón MT; Selva JC; Figueredo J; Vaquer J; Toledo C; Quintanal N; Salva S; Domíngez R; Alert J; Marinello JJ; Catalá M; Griego MG; Martell JA; Luaces PL; Ballesteros J; de-Castro N; Bach F; Crombet T
    BMC Cancer; 2013 Jun; 13():299. PubMed ID: 23782513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients - A Czech multicenter experience.
    Weinbergerová B; Demel I; Víšek B; Válka J; Čerňan M; Jindra P; Novák J; Stejskal L; Kovácsová F; Kabut T; Szotkowski T; Hájek R; Žák P; Cetkovský P; Král Z; Mayer J
    Hematol Oncol; 2022 Apr; 40(2):280-286. PubMed ID: 35120267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized clinical trial to compare the efficacy of ivermectin versus placebo to negativize nasopharyngeal PCR in patients with early COVID-19 in Peru (SAINT-Peru): a structured summary of a study protocol for randomized controlled trial.
    Garcia PJ; Mundaca H; Ugarte-Gil C; Leon P; Malaga G; Chaccour C; Carcamo CP
    Trials; 2021 Apr; 22(1):262. PubMed ID: 33836826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.
    Garcia-Vicuña R; Abad-Santos F; González-Alvaro I; Ramos-Lima F; Sanz JS
    Trials; 2020 Sep; 21(1):772. PubMed ID: 32907638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma.
    Bartels U; Wolff J; Gore L; Dunkel I; Gilheeney S; Allen J; Goldman S; Yalon M; Packer RJ; Korones DN; Smith A; Cohen K; Kuttesch J; Strother D; Baruchel S; Gammon J; Kowalski M; Bouffet E
    Neuro Oncol; 2014 Nov; 16(11):1554-9. PubMed ID: 24847085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care setting (LIBERTY): A structured summary of a study protocol for a randomised controlled trial.
    Vainio PJ; Hietasalo P; Koivisto AL; Kääriäinen S; Turunen J; Virtala M; Vuorinen J; Scheinin M
    Trials; 2021 Jan; 22(1):44. PubMed ID: 33430933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bamlanivimab use in mild-to-moderate COVID-19 disease: A matched cohort design.
    Destache CJ; Aurit SJ; Schmidt D; Peet Erkes L; Tierney M; Vivekanandan R
    Pharmacotherapy; 2021 Sep; 41(9):743-747. PubMed ID: 34328670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.